Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 3/20 | 0.74 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.74 |
| ▸ | SLC2A1 | P11166 | 16/20 | 0.68 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17719026 | 0.85 | KCNK3 (1.00) | KCNK3KCNK9SLC2A1SLC2A2 | |
| SCHEMBL22269718 | 0.83 | SLC2A1 (0.77) | KCNK3KCNK9SLC2A1SLC2A2MEN1 | |
| SCHEMBL17718860 | 0.81 | SLC2A1 (1.00) | KCNK3KCNK9SLC2A1SLC2A2KDM4E | |
| SCHEMBL17718958 | 0.80 | KCNK3 (1.00) | KCNK3KCNK9SLC2A1SLC2A2 | |
| SCHEMBL17718956 | 0.79 | SLC2A1 (1.00) | KCNK3KCNK9SLC2A1SLC2A2 | |
| SCHEMBL17719179 | 0.79 | SLC2A2 (0.85) | KCNK3KCNK9SLC2A1SLC2A2 | |
| SCHEMBL17718999 | 0.79 | SLC2A1 (1.00) | SLC2A1SLC2A2KDM4EHTT | |
| SCHEMBL17719158 | 0.78 | KCNK3 (0.80) | KCNK3KCNK9SLC2A1SLC2A2 | |
| SCHEMBL17719024 | 0.78 | KCNK3 (0.82) | KCNK3KCNK9SLC2A1SLC2A2 | |
| SCHEMBL17718955 | 0.78 | SLC2A1 (1.00) | KCNK3KCNK9SLC2A1SLC2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759794-B2 | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-A]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759794-B2 | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-A]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders | TRPV2, CACNA1G, KCNJ2 | KCNK3 85/4885KCNK9 204/4885SLC2A1 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.